#1 Clinical Trials Search in Europe

Lenacapavir

Lenacapavir is an innovative HIV drug being studied in multiple clinical trials for both treatment and prevention of HIV infection. As a long-acting capsid inhibitor, lenacapavir offers the potential for less frequent dosing compared to traditional daily antiretroviral medications. This article summarizes key information from ongoing clinical trials evaluating lenacapavir’s safety, efficacy, and acceptability in various populations.

Table of Contents

What is Lenacapavir?

Lenacapavir is a new medication being developed for the treatment of HIV-1 infection. It’s also known by its research names GS-6207 and GS-6207[1][2]. HIV-1 (Human Immunodeficiency Virus type 1) is the most common type of HIV, which is the virus that causes AIDS if left untreated. Lenacapavir represents a new class of HIV drugs called capsid inhibitors, which work differently from other available HIV medications[3].

How Does Lenacapavir Work?

Lenacapavir is a capsid inhibitor. The capsid is a protein shell that protects the genetic material of the HIV virus. By interfering with the capsid, lenacapavir disrupts multiple stages of the HIV life cycle, making it harder for the virus to replicate and spread in the body[3]. This unique mechanism of action makes lenacapavir effective against HIV strains that may be resistant to other types of antiretroviral drugs.

Conditions Treated by Lenacapavir

Lenacapavir is primarily being developed to treat HIV-1 infection. It’s being studied in various patient groups, including:

  • People who are newly diagnosed with HIV-1 and haven’t started treatment yet (treatment-naive)[1]
  • People who have been on HIV treatment before but are experiencing difficulties with their current regimen (treatment-experienced)[1]
  • People with multi-drug resistant HIV who have limited treatment options[3]
  • People who are virologically suppressed (have very low levels of HIV in their blood) but are on complex treatment regimens[9]

Additionally, lenacapavir is being studied for use in HIV pre-exposure prophylaxis (PrEP). PrEP is a strategy where people who don’t have HIV take medication to prevent getting infected with the virus[5][6][7].

How is Lenacapavir Administered?

One of the unique features of lenacapavir is its long-acting formulation. It can be administered in two main ways:

  1. Oral tablets: Lenacapavir can be taken as tablets by mouth. These are usually used for initial dosing or “loading doses”[1][2].
  2. Subcutaneous injection: After initial oral doses, lenacapavir can be given as an injection under the skin (subcutaneously) in the abdomen. This long-acting formulation can last for several months, potentially allowing for dosing only twice a year[1][2].

This long-acting formulation could be a game-changer for HIV treatment, potentially improving adherence to medication regimens and quality of life for people living with HIV[5][6][7].

Clinical Trials and Research

Lenacapavir is currently being studied in several clinical trials to evaluate its safety and effectiveness. Some key findings from these trials include:

  • In a study of people with multi-drug resistant HIV, lenacapavir showed promising antiviral activity when added to a failing regimen[3].
  • Studies are looking at the effectiveness of lenacapavir in combination with other antiretroviral drugs for long-term HIV treatment[8].
  • Research is ongoing to evaluate lenacapavir’s potential for HIV prevention (PrEP) in various populations, including women and people who inject drugs[5][6][7].
  • Studies are assessing the drug’s effectiveness in simplifying treatment for people who are already virologically suppressed but on complex regimens[9].

Combination Therapies with Lenacapavir

HIV is typically treated with a combination of medications to attack the virus in multiple ways. Lenacapavir is being studied in combination with various other HIV drugs, including:

  • Bictegravir: An integrase inhibitor that prevents HIV from inserting its genetic material into human cells[9][10].
  • Emtricitabine and Tenofovir: Nucleoside reverse transcriptase inhibitors that interfere with HIV replication[5][6][7].
  • Broadly neutralizing antibodies: These are antibodies that can neutralize many different strains of HIV. Lenacapavir is being studied in combination with two such antibodies, teropavimab and zinlirvimab[1][2].

Safety and Side Effects

As with all medications, lenacapavir can potentially cause side effects. Clinical trials are closely monitoring the safety of lenacapavir. Some of the aspects being studied include:

  • The occurrence of adverse events (unwanted side effects)[1][2][3].
  • Changes in laboratory test results, such as blood tests[1][2][3].
  • The development of resistance to lenacapavir[1][3].
  • The body’s immune response to lenacapavir, including the potential development of antibodies against the drug[1][2].

It’s important to note that the full safety profile of lenacapavir is still being established through ongoing clinical trials.

Future Developments and Potential

Lenacapavir represents an exciting development in HIV treatment and prevention. Its unique mechanism of action and long-acting formulation could potentially offer several benefits:

  • Simplified treatment regimens, potentially improving adherence and quality of life for people living with HIV[9].
  • New options for people with multi-drug resistant HIV[3].
  • Long-acting HIV prevention (PrEP) options, which could make HIV prevention easier and more accessible[5][6][7].
  • Potential for use in different populations, including adults, adolescents, and children living with HIV[10].

As research continues, we’ll learn more about the full potential of lenacapavir in transforming HIV treatment and prevention.

Aspect Details
Study Populations – Treatment-experienced adults with multidrug-resistant HIV – Virologically suppressed adults and adolescents – HIV-negative individuals for PrEP – Cisgender women – Children and adolescents with HIV-1
Dosing Forms – Oral tablets (600 mg loading dose, 300 mg maintenance) – Subcutaneous injection (927 mg every 6 months)
Key Outcomes Measured – Safety and tolerability – Viral suppression rates – Pharmacokinetics – Patient acceptability and satisfaction – Prevention efficacy for PrEP
Combination Therapies – Lenacapavir + optimized background regimen – Lenacapavir + broadly neutralizing antibodies (bNAbs) – Bictegravir/Lenacapavir fixed-dose combination
Unique Features – Long-acting formulation (6-month dosing) – Novel mechanism of action – Potential for treating multidrug-resistant HIV – Being studied for both treatment and prevention

FAQ

  • What is lenacapavir and how does it work? Lenacapavir is a first-in-class HIV capsid inhibitor. It works by interfering with multiple stages of the HIV life cycle, including blocking the virus's ability to properly assemble, release, and enter new cells. This unique mechanism allows lenacapavir to maintain antiviral activity against HIV strains resistant to other drug classes.
  • How is lenacapavir administered? Lenacapavir can be given as an oral tablet or as a long-acting subcutaneous injection. The injectable form is typically administered every 6 months, offering a potential advantage over daily oral medications.
  • What populations are being studied in lenacapavir clinical trials? Clinical trials are evaluating lenacapavir in diverse populations, including treatment-experienced adults with multidrug-resistant HIV, virologically suppressed adults and adolescents, and HIV-negative individuals for pre-exposure prophylaxis (PrEP). Some studies focus specifically on women or pediatric patients.
  • What are some potential benefits of lenacapavir? Potential benefits include less frequent dosing (every 6 months for injections), efficacy against drug-resistant HIV strains, and a novel mechanism of action. This may improve treatment adherence and provide new options for people with limited treatment choices due to resistance.
  • What are researchers evaluating in these clinical trials? Key areas of focus include lenacapavir's safety profile, efficacy in suppressing HIV viral load, pharmacokinetics (how the drug moves through the body), acceptability to patients, and ability to prevent HIV infection when used as PrEP. Some trials are also assessing quality of life measures and comparing lenacapavir to standard antiretroviral regimens.

Ongoing Clinical Trials on Lenacapavir

  • Study of Bictegravir and Lenacapavir for Children and Adolescents with HIV-1

    Recruiting

    4 1 1 1
    Investigated drugs:
    Italy Spain

  • Study on Lenacapavir for HIV Prevention in Individuals at Risk of HIV Infection

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study to Compare Weekly Islatravir/Lenacapavir with Bictegravir/Emtricitabine/Tenofovir in People with HIV-1 Who Are Virologically Suppressed

    Not recruiting

    3 1 1
    Investigated drugs:
    France Germany Spain

  • Study on Long-Acting Cabotegravir and Lenacapavir for HIV Patients: Evaluating Dual Antiretroviral Therapy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Bictegravir/Lenacapavir to Current Therapy in People with HIV-1 Who Are Successfully Treated

    Not recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study Comparing Bictegravir and Lenacapavir to Current Treatment in Patients with HIV-1 on Complex Regimens

    Not recruiting

    4 1 1 1
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Lenacapavir (LEN): A novel HIV capsid inhibitor being studied for both treatment and prevention of HIV infection. It can be given orally or as a long-acting subcutaneous injection.
  • Capsid inhibitor: A class of antiretroviral drugs that interfere with the HIV capsid protein, which is essential for the virus's structure and life cycle.
  • Antiretroviral therapy (ART): The use of HIV medicines to treat HIV infection, typically involving a combination of drugs from different classes.
  • Virologically suppressed: A state where antiretroviral therapy has reduced a person's HIV viral load to very low or undetectable levels.
  • Multidrug-resistant HIV: HIV strains that have developed resistance to multiple classes of antiretroviral drugs, making them more difficult to treat.
  • Pre-exposure prophylaxis (PrEP): The use of antiretroviral medications by HIV-negative individuals to reduce their risk of acquiring HIV infection.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Fixed-dose combination (FDC): A pill that combines two or more drugs in fixed doses.
  • Optimized background regimen (OBR): A personalized combination of antiretroviral drugs chosen based on a patient's treatment history and resistance profile.

References

  1. https://clinicaltrials.gov/study/NCT04811040
  2. https://clinicaltrials.gov/study/NCT05729568
  3. https://clinicaltrials.gov/study/NCT04150068
  4. https://clinicaltrials.gov/study/NCT06101329
  5. https://clinicaltrials.gov/study/NCT06532656
  6. https://clinicaltrials.gov/study/NCT06513312
  7. https://clinicaltrials.gov/study/NCT06101342
  8. https://clinicaltrials.gov/study/NCT04143594
  9. https://clinicaltrials.eu/trial/study-comparing-bictegravir-and-lenacapavir-to-current-treatment-in-patients-with-hiv-1-on-complex-regimens/
  10. https://clinicaltrials.gov/study/NCT03739866